According to an editorial, this network meta-analysis does the field a great service in that it makes clear how few PTSD trials there have been and clarifies that more are needed. It notes that for a disorder widely acknowledged as an important public health problem, the lack of PTSD trials, particularly ones evaluating pharmacotherapies, is troubling. Equally concerning is the small size of the trials that have been funded, comparted to clinical trials in other serious disease states. It adds that there is some evidence that patient preference matters in the initial selection of treatment, but clinicians are unsure what to do when that first treatment fails: add a second treatment? (which one?) or switch to another evidence-based treatment?